obinutuzumab,rituximab,zanubrutinib,lenalidomide
beigene,roche
['rosewood', 'zanubrutinib', 'mahogany', 'obinu', 'lymsm']
rosewood study in r/r fl presented by pier zinzani showing improved ttnt for zanubrutinib + obinutuzumab although no os benefit; no increased safety signals compared to obinu alone, with upcoming results from phiii mahogany study #17icml #lymsm 
Heme/Onc fellow @UCCancerCenter interested in aggressive lymphoma, novel therapeutics, and cellular therapies #lymsm #TcellRx. Views are my own.